These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

123 related items for PubMed ID: 30744698

  • 1. Antitumor response to microscopic melanoma in the gastric mucosa mimicking ipilimumab-induced gastritis.
    Bello E, Cohen JV, Mino-Kenudson M, Dougan M.
    J Immunother Cancer; 2019 Feb 11; 7(1):41. PubMed ID: 30744698
    [Abstract] [Full Text] [Related]

  • 2. Intraepithelial Melanoma in the Stomach After Treatment With Immune Checkpoint Blockade Therapy.
    Shustef E, Torres-Cabala CA, Curry JL, Tetzlaff MT, Nagarajan P, Ivan D, Prieto VG, Aung PP.
    Am J Dermatopathol; 2017 Aug 11; 39(8):e116-e118. PubMed ID: 28248716
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. Cytomegalovirus gastritis as a rare adverse event during combined ipilimumab and nivolumab in a patient with melanoma.
    Indini A, Gueli R, Cerati M, Rijavec E, Parravicini M, Casagrande S, Rovelli C, Grossi PA, Grossi F.
    Melanoma Res; 2024 Aug 01; 34(4):386-389. PubMed ID: 38768445
    [Abstract] [Full Text] [Related]

  • 5. A rare case of eosinophilic gastritis induced by nivolumab therapy for metastatic melanoma.
    Tsuji A, Hiramatsu K, Namikawa S, Yamamoto A, Midori Y, Murata Y, Tanaka T, Nosaka T, Naito T, Takahashi K, Ofuji K, Matsuda H, Ohtani M, Imamura Y, Iino S, Hasegawa M, Nakamoto Y.
    Clin J Gastroenterol; 2022 Oct 01; 15(5):876-880. PubMed ID: 35978213
    [Abstract] [Full Text] [Related]

  • 6. Dual checkpoint inhibitor-associated eosinophilic enteritis.
    Yang J, Lagana SM, Saenger YM, Carvajal RD.
    J Immunother Cancer; 2019 Nov 15; 7(1):310. PubMed ID: 31730503
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Metastatic uveal melanoma showing durable response to anti-CTLA-4 and anti-PD-1 combination therapy after experiencing progression on anti-PD-1 therapy alone.
    Afzal MZ, Mabaera R, Shirai K.
    J Immunother Cancer; 2018 Feb 12; 6(1):13. PubMed ID: 29433557
    [Abstract] [Full Text] [Related]

  • 10. Combined immune checkpoint blockade for metastatic uveal melanoma: a retrospective, multi-center study.
    Heppt MV, Amaral T, Kähler KC, Heinzerling L, Hassel JC, Meissner M, Kreuzberg N, Loquai C, Reinhardt L, Utikal J, Dabrowski E, Gesierich A, Pföhler C, Terheyden P, Thoms KM, Zimmer L, Eigentler TK, Kirchberger MC, Stege HM, Meier F, Schlaak M, Berking C.
    J Immunother Cancer; 2019 Nov 13; 7(1):299. PubMed ID: 31722735
    [Abstract] [Full Text] [Related]

  • 11. Neurologic Serious Adverse Events Associated with Nivolumab Plus Ipilimumab or Nivolumab Alone in Advanced Melanoma, Including a Case Series of Encephalitis.
    Larkin J, Chmielowski B, Lao CD, Hodi FS, Sharfman W, Weber J, Suijkerbuijk KPM, Azevedo S, Li H, Reshef D, Avila A, Reardon DA.
    Oncologist; 2017 Jun 13; 22(6):709-718. PubMed ID: 28495807
    [Abstract] [Full Text] [Related]

  • 12. Acute visual loss after ipilimumab treatment for metastatic melanoma.
    Wilson MA, Guld K, Galetta S, Walsh RD, Kharlip J, Tamhankar M, McGettigan S, Schuchter LM, Fecher LA.
    J Immunother Cancer; 2016 Jun 13; 4():66. PubMed ID: 27777775
    [Abstract] [Full Text] [Related]

  • 13. Clonal expansion of CD8 T cells in the systemic circulation precedes development of ipilimumab-induced toxicities.
    Subudhi SK, Aparicio A, Gao J, Zurita AJ, Araujo JC, Logothetis CJ, Tahir SA, Korivi BR, Slack RS, Vence L, Emerson RO, Yusko E, Vignali M, Robins HS, Sun J, Allison JP, Sharma P.
    Proc Natl Acad Sci U S A; 2016 Oct 18; 113(42):11919-11924. PubMed ID: 27698113
    [Abstract] [Full Text] [Related]

  • 14. Autoimmune polyradiculitis due to combination immunotherapy with ipilimumab and nivolumab for the treatment of metastatic melanoma.
    Lasocki A, Smith K.
    J Clin Neurosci; 2020 Apr 18; 74():240-241. PubMed ID: 31983645
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Ipilimumab plus nivolumab for patients with metastatic uveal melanoma: a multicenter, retrospective study.
    Najjar YG, Navrazhina K, Ding F, Bhatia R, Tsai K, Abbate K, Durden B, Eroglu Z, Bhatia S, Park S, Chowdhary A, Chandra S, Kennedy J, Puzanov I, Ernstoff M, Vachhani P, Drabick J, Singh A, Xu T, Yang J, Carvajal R, Manson D, Kirkwood JM, Cohen J, Sullivan R, Johnson D, Funchain P, Shoushtari A.
    J Immunother Cancer; 2020 Jun 18; 8(1):. PubMed ID: 32581057
    [Abstract] [Full Text] [Related]

  • 17. Seronegative autoimmune autonomic ganglionopathy from dual immune checkpoint inhibition in a patient with metastatic melanoma.
    Gao CA, Weber UM, Peixoto AJ, Weiss SA.
    J Immunother Cancer; 2019 Oct 17; 7(1):262. PubMed ID: 31623673
    [Abstract] [Full Text] [Related]

  • 18. [Acutely induced diabetes mellitus in a 63-year-old female after treatment with ipilimumab for metastatic melanoma].
    Jørgensen LB, Yderstræde K.
    Ugeskr Laeger; 2017 Sep 11; 179(37):. PubMed ID: 28918779
    [Abstract] [Full Text] [Related]

  • 19. Immune-Related Adverse Events (irAEs): Diagnosis, Management, and Clinical Pearls.
    Darnell EP, Mooradian MJ, Baruch EN, Yilmaz M, Reynolds KL.
    Curr Oncol Rep; 2020 Mar 21; 22(4):39. PubMed ID: 32200442
    [Abstract] [Full Text] [Related]

  • 20. Lymphocytic gastritis induced by pembrolizumab in a patient with metastatic melanoma.
    Yip RHL, Lee LH, Schaeffer DF, Horst BA, Yang HM.
    Melanoma Res; 2018 Dec 21; 28(6):645-647. PubMed ID: 30256271
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 7.